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Abstract
In Obstetrics and Gynecology, the practice of biologic hemostatic agents in the 
field are generally used to augment the basic tenets of hemostasis to decrease the 
morbidity and mortality of such procedures. These hemostatic agents work along 
with the body’s physiology to rapidly aid in platelet plug formation, activation of 
the clotting cascade, the creation of fibrin, and to form a stable clot. The four main 
sub-categories of hemostatic agents include mechanical, biological, flowable, and 
fibrin sealants. Mechanical agents act as scaffolding for platelet aggregation to form 
a platelet plug. Biological agents activate clotting factors in the coagulation cascade 
to aid in hemostasis. Flowable agents combine biologic with mechanical agents to 
stabilize clot formation while also providing mechanical tamponade. Fibrin sealants 
combine high levels of fibrin and thrombin that when combined, form a fibrin clot 
at an accelerated speed. Hemostatic agents in obstetrics are often used in the setting 
of postpartum hemorrhage, cesarean delivery and postpartum hysterectomy to 
decrease the rate of morbidity most commonly seen with abnormal placentation 
and uterine atony. With gynecologic surgery, hemostatic agents are more commonly 
used then in obstetrics. They aid in hemostasis with common gynecologic proce-
dures including hysterectomies, ovarian cystectomies, myomectomies, endometrio-
sis cases, incontinence procedures and malignant debulking procedures. Also, with 
the increase in minimally invasive surgical techniques, topical hemostasis can aid in 
fewer transfusions, improved visualization in the surgical field decreased operative 
time and reduction in the risk of conversion to laparotomy.
Keywords: obstetrics, gynecology, postpartum hemorrhage, cesarean delivery, 
hysterectomy, ovarian cystectomies, myomectomies, endometriosis, malignant 
debulking, minimally invasive gynecology, hemostasis, mechanical hemostasis, 
platelet plug formation, biologic agents, thrombin, gelatins, oxidized regenerated 
cellulose, collagen, microporous polysaccharide spheres, fibrin sealants
1. Introduction
Intraoperative hemostasis is primarily achieved through knowledge of anatomy 
and good surgical technique. Technology has augmented the basic tenets of surgical 
hemostasis since 1926 and has continued to evolve. In addition to applying pressure 
and using suture, there are now a wide variety of hemostatic options available to 
gynecologic surgeons including monopolar/bipolar cautery, harmonic technology, 
hemoclips, laser, argon beam coagulation, tacks, and topical hemostatic agents. Like 
any other trade, it is important to have the right tool for the job. If there is bleeding 
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in a sensitive anatomic location in the pelvis, mechanical and thermal techniques 
may not be practical given the risk to adjacent tissues. Topical hemostatic agents 
have been available since the mid 20th century and can act as an adjunct to provide 
both active and passive hemostasis in situations where bleeding is difficult or 
impractical to be controlled by conventional methods. Topical hemostatic agents 
work by augmenting specific parts of physiologic hemostasis. Of the four phases 
of hemostasis [1, 2], topical hemostatic agents primarily affect formation of the 
platelet plug and propagation of the coagulation cascade. Topical hemostatic agent 
use is common practice in many surgical procedures, and has been utilized across all 
surgical specialties [3]. Likely due to marketing, usage of topical hemostatic agents 
has increased by 10–21% since 2000 [4]. This chapter will focus on use of topical 
hemostatic agents in obstetrics/gynecological surgeries with a focus on postpar-
tum hemorrhage, myomectomy, hysterectomy, endometriosis surgery, oncologic 
debulking, and ovarian cystectomy.
2. Hemostatic mechanisms
In order to understand the mechanism of action of topical hemostatic agents, it 
is important to understand the basic physiology of hemostasis. There are four main 
phases of hemostasis: endothelial injury and platelet plug formation, activation of 
the clotting cascade, termination of the clotting, and fibrinolysis [3]. Hemostasis 
represents a delicate and regulated balance between thrombosis and thrombolysis. 
Formation of a stable hemostatic clot relies on a complex interaction between vaso-
constriction, circulating clotting factors, and platelet factors. In a surgical patient, 
the inciting event is endothelial damage from trauma. Injury to the endothelium 
exposes blood to subendothelial elements that promote platelet adhesion and acti-
vation. Endothelial injury also activates both the extrinsic and intrinsic coagulation 
pathways through increased expression of tissue factor and exposure to negatively 
charged surfaces respectively.
After vessel injury, there is temporary vasoconstriction which facilitates plate-
let adhesion and subsequent activation. This forms a fragile platelet plug which 
requires stabilization during secondary hemostasis to form a clot. Initiation of the 
coagulation cascade occurs through both extrinsic and intrinsic pathways. This 
involves multiple plasma proteins, calcium ions, and platelets. At the end of the 
cascade, thrombin ultimately converts fibrinogen to fibrin leading to a stable clot 
[5]. This is critical as thrombin can be applied alone or in combination with other 
hemostatic agents, bypassing the intrinsic and extrinsic pathways as long as there is 
adequate circulating fibrinogen present.
3. Hemostatic agents
There are four sub-categories of hemostatic agents utilized. These include 
mechanical, biological, flowable, and fibrin sealant. They each have different prop-
erties and associated cost [6]. Although there are different mechanisms of action, 
these topical hemostatic agents act by augmenting the first phase of coagulation 
(platelet plug formation) and/or stimulating the production of fibrin for clot stabi-
lization. Agents that both stimulate platelet plug formation and contain thrombin 
are the most effective at creating hemostasis but are the most costly. Table 1 pro-
vides a summary of the agents discussed in this chapter. The four sub-categories of 
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Creates a scaffolding for 
platelet aggregation, lowers pH 
to activate clotting cascade
1–2 weeksΔ Foreign body reaction, 
infection, adhesions [3]
$





Expands to provide a matrix 
for clot formation, can act as a 
sponge to absorb blood, some 
contain thrombin to activate 
clotting cascade.
4–6 weeks Infection, abscess or 
granuloma formation, 
fibrosis, clot disruption 












Acts as scaffolding for platelet 
aggregation







Plant Powder Arista, Vitasure, 
Hemostase
Absorbs water to concentrate 
platelets and accelerate clot 
formation
< 48 hours Can alter glucose loads 
in diabetic patient if 
used excessively
$
Fibrin Sealants⋄ Pooled human plasma, 
Pooled human and equine 
collagen, Individual 
human plasma with bovine 
collagen and thrombin
Liquid Tisseel, Evicel, 
Tachosil, Vitagel
Contain high levels of 
fibrinogen and thrombin 
separately that when combined 
form a fibrin clot at an 
accelerated speed
Immediate Potential exposure to 
blood borne viruses
$$$
*Severe hypersensitivity reactions and antibody formation can occur with use of protein-containing topical hemostatic and fibrin sealants; more evident with repeated application.
¶Price range (US dollars): $:50 to 100 dollars, $$ 101 to 300 dollars, $$$: 301 to 500 dollars; Cost is highly variable and subject to institutional contractual agreements.
ΔDelayed resorption can occur with oxidized regenerated cellulose due to the low pH which inhibits proteases and elastases. May delay for more than 2 weeks.
◊Fibrinogen concentration are higher for commercial preparations (Tisseel 70 mg/mL and Evicel 55 to 85 mg/mL) as compared to unmanipulated cryoprecipitate (2.5 to 25 mg/mL) [10, 11].
Table 1.
Biologic hemostatic agents.
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3.1 Mechanical
When normal mechanical techniques for maintaining hemostasis such as pres-
sure, sutures, clips, gauze sponges fail or cannot be used due to sensitive anatomic 
location, mechanical topical hemostatic agents can be used alone or in combination 
(not all mechanical products) with thrombin. Mechanical agents act as a scaf-
fold for platelet aggregation and can dehydrate the injury bed allowing for a local 
increase in clotting factors. This type of hemostatic agent when used alone acts 
passively to control hemostasis which means that an intact clotting cascade is neces-
sary for adequate clot stabilization. The properties of the most common topical 
mechanical hemostatic agents are listed below and included in Table 1. Clinically, 
these agents are useful with heavier bleeding (especially if combined with an active 
hemostatic agent like thrombin) because they can absorb multiple times their 
weight in fluid [12]. Given expansion of these agents, caution should be exercised 
when applying them in anatomic locations where there is risk for nerve injury. If 
these agents are needed near nerves, it is recommended that after hemostasis is 
achieved, residual agent is removed [13]. Although it is not possible to conduct 
randomized trials with topical hemostatic agents, one study evaluated many of 
these mechanical agents in vitro and found that microfibrillar collagen was the most 
effective followed by collagen sponge, gelatin sponge and oxidized regenerated 
cellulose [14].
Use of mechanical hemostatic agents can mimic abcess formation on postopera-
tive imaging [15]. Interpretation as to whether its abscess versus normal degenera-
tion of topical hemostatic agents may be aided by informing radiologist that topical 
hemostatic agents have been used [16]. An abscess typically has rim enhanced and 
air-fluid levels. Topical hemostatic agent degeneration usually has tightly packed 
gas bubbles which remain unchanged on serial exams with no rim enhancement or 
air-fluid levels [16]. Often, as mechanical hemostatic agents degenerate over time, 
they may be mistaken as granulomas or malignancy [17, 18].
1. Oxidized Regenerated Cellulose (ORC) (Surgicel, Surgicell Fibrillar,Nu-Knit)
This type of mechanical agent is used in cases of relatively light venous bleeding. 
Minimal preparation is required, and it is the least expensive of hemostatic agents 
utilized. ORC can be used in heparinized patients although efficacy in thrombo-
cytopenic patients is limited [19].
When applied directly to tissue, oxidized regenerated cellulose creates a 
scaffold for platelet aggregation. By decreasing tissue pH, it works to further 
hemostasis by activating the clotting cascade. The decreased pH may have an 
additional benefit: bactericidal activity [5]. This agent, however, should not be 
used with biologic agents (Thrombin) [3].
Oxidized Regenerated Cellulose comes in different forms: Powder, cloth, 
foam, and sponge. These are absorbed in 14 days but can persist up to 1 year 
[14]. The cloth form of ORC is easily rolled and can be placed through a laparo-
scopic trocar. These agents may also help to prevent development of adhesions 
although evidence to support this is limited [20] It should be noted that ORC 
has been associated with abscess formation.
2. Gelatins (Gelfoam,Surgifoam)
Made from porcine collagen, gelatin hemostatic agents, comprised of powder 
or foam, can be saturated with normal saline to form a paste [9]. These agents 
provide a matrix for clot formation and can expand up to 200%. When applied 
directly to tissue, these agents can act as a sponge to absorb blood. Clotting oc-
5
Biologic Hemostatic Agents in Obstetrics and Gynecology
DOI: http://dx.doi.org/10.5772/intechopen.96969
curs through contact activation as the gelatin particles restrict blood flow and 
provide a stable matrix for a clot to form [21]. Pressure is necessary for several 
minutes for optimal hemostasis. Pressure will also keep the gelatin from  
dislodging [19].
Gelatins are absorbed within 4–6 weeks. These agents can also be passed 
through laparoscopic trocars. Because these agents have a neutral pH they can 
be used with biologic agents [7]. Gelatins are frequently (and easily) combined 
with activated thrombin to augment hemostasis if there is brisk bleeding.
3. Microfibrillar Collagen (bovine collagen) –Avitene, Avitene Ultrafoam,Avitene 
Ultrawrap, Helitene,Helistat)
Microfibrillar collagen is applied directly to tissue and acts as a scaffolding 
for platelet aggregation [3]. These agents are available as a sheet, powder, or 
sponge. They can be difficult to handle, however, because they tend to stick 
to gloves and instruments [14]. These agents are absorbed in 2–3 months. 
Combining microfibrillar collagen with thrombin or saline may reduce the 
hemostatic efficacy of the microfibrillar collagen. It is important to note that 
granulomatous reactions with microfibrillar collagens have been linked to 
bowel obstruction and surgical re-exploration.
4. Microporous Polysaccharide spheres (Arista, Vitasure, Hemostase)
These agents are made from potato starch and are available in powder form for 
laparoscopic application [3]. By absorbing water, these agents work to con-
centrate platelets to accelerate clot formation. It can be applied to the surgical 
field with gentle pressure. These agents are absorbed within 48 hours limiting 
potential for lasting complications such as abscess formation or bowel obstruc-
tion [3]. These agents are not meant to be combined with activated thrombin 
as adding liquid will impair the ability of the starch to absorb water in the field. 
Laparoscopic applicators are available to spray the starch intraabdominally 
during laparoscopic surgery. As these agents are made from potato starch, they 
are inexpensive.
3.2 Biological
Bovine thrombin (Thrombin-jmi), Pooled human thrombin (Evithrom), 
Recombinant thrombin (Recothrom).
Biological hemostatic agents are active agents that work to provide hemostasis by 
activating clotting factors in the final stages of the coagulation cascade. Thrombin 
is activated by calcium and as noted previously acts to convert fibrinogen to fibrin, 
stabilizing the clot. Although activated thrombin does not require circulating 
clotting factors to work, it will not be effective if there is hypofibrinogenemia which 
is often seen in cases of disseminated intravascular coagulation (DIC). Bovine 
thrombin has been approved for use since the 1970s. Thrombin alone is indicated 
for localized, minor bleeding and is dispersed as a liquid spray. Thrombin can be 
reconstituted from a powder or thawed from frozen formulations to form a liquid 
or paste which can then be applied alone or in conjunction with absorbable gelatin 
[22–24]. In obstetrical and gynecological surgery, thrombin is rarely used alone. 
Fibrinogen was combined with concentrated plasma thrombin in the late 1990s 
creating a fibrin sealant [25]. Fibrin sealants can also contain a matrix to support 
platelet aggregation and activation. From a biologic perspective, fibrin sealants are 
more likely to provide hemostasis in case of coagulopathy/DIC because fibrinogen is 
supplied with thrombin. Combining active (thrombin or thrombin with fibrinogen) 
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with a passive hemostatic agent can significantly improve hemostasis. In vitro 
and clinical studies have demonstrated faster hemostasis with the use of active 
hemostatic agents [26, 27]. Active hemostatic agents are uniformly more costly 
than mechanical (passive) hemostatic agents. The risks of using human or bovine 
products is low Flowable-Floseal, Gelfoam.
When thrombin is combined with gelatin granules, hemostasis can be achieved 
on wet, actively bleeding tissue. As gelatin capsules swell, this leads to mechanical 
tamponade (passive). Thrombin then converts patients’ fibrinogen to fibrin further 
stabilizing the clot. These agents require intraoperative preparation and are applied 
with paste like consistency [24]. Flowable agents may contribute to adhesive disease 
and may be associated with small bowel obstruction [28, 29]. They are typically 
absorbed in 6–8 weeks and can sometimes be mistaken for abscess on postoperative 
imaging. Products like floseal are available with a laparoscopic applicator to facili-
tate placement of the agent during complicated laparoscopic surgery.
3.3 Fibrin sealants
Pooled human plasma (Tisseel, Evicel), Pooled human and equine collagen 
(Tachosil), Individual human plasma with bovine collagen and thrombin (Vitagel).
Fibrin sealants provide high levels of fibrinogen and thrombin separately that 
when combined form a fibrin clot at an accelerated speed. Fibrin sealants are 
comprised of 2 parts: a sealer protein solution containing aprotinin, factor XII, 
and fibrinogen, and a second component containing thrombin. Concentration of 
fibrinogen determines strength of sealant, and thrombin determines speed of clot 
formation [14]. Fibrin sealants are very effective and are best used for bleeding 
from large surfaces such as diffuse peritoneal bleeding after removal of a mass/
malignancy. In a randomized trial of 224 patients comparing fibrin sealant to ORC 
for bleeding after liver resection, 81% acquired hemostasis in 3 mins versus 50% 
with ORC [30]. Fibrin sealants have also been used off-label as an adhesion barrier, 
but this is controversial and expensive.
4.  Practical usage of topical hemostatic agents in obstetrics and 
gynecology
Selection of a particular topical hemostatic agent in Ob/Gyn depends entirely 
on the clinical situation, local availability of agents, and cost considerations. There 
is no “one size fits all” agent. The ideal topical hemostatic agent will control hemo-
stasis rapidly, have a low risk of adverse events, be easy to prepare and handle, and 
be compatible with any patient factors [12]. Examples of practical usage of topical 
hemostatic agents in Ob/Gyn are provided in the following sections.
4.1 Obstetrical usage
In obstetrics, topical hemostatic agents are most often used to control postpar-
tum hemorrhage in the setting of postpartum hysterectomy. Hemorrhage at time of 
cesarean section is the leading cause of morbidity. Eight percent of maternal deaths 
are due to postpartum hemorrhage in the United States [31]. Common indications 
for postpartum hysterectomy include abnormal placentation and uterine atony. 
Abnormal placentation has replaced uterine atony as the most common indication 
leading to emergency postpartum hysterectomy [31]. Placenta accreta now occurs 
in as many as 1 in 553 pregnancies. Topical hemostatic agents may be applied if 
traditional techniques for controlling postpartum hemorrhage such as: uterotonic 
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agents, vessel ligation, packing, balloon tamponade, over–sewing the placental bed, 
compression sutures, or uterine artery embolization are not successful. Topical 
hemstatic agents may be particularly helpful in cases of placenta previa with lower 
segment and implantation site bleeding. Bleeding can be brisk and present over 
large surfaces in these cases. Additionally, patients with hemorrhage can have factor 
and fibrinogen deficiencies. Therefore, fibrin sealants and agents that have both 
mechanical and biological properties are preferred. Hemorrhage at time of cesarean 
section is the leading cause of morbidity. 8% maternal deaths are due to postpartum 
hemorrhage in the United States [31]. With the statistics provided above, excel-
lent hemostasis has become imperative for the safety and well being of obstetrical 
patients.
In 2007, Moriarty, et al. [32], presented a case reporting the use of topical hemo-
static agents in massive postpartum hemorrhage. In this case the patient had a cesar-
ean section for placental abruption. Due to persistent uterine atony and hemorrhage 
unresponsive to typical management techniques, she underwent a total abdominal 
hysterectomy. This was complicated by DIC with persistent bleeding from venous 
plexus at vaginal vault. FloSeal, a flowable hemostatic agent, was applied and 
hemostasis was achieved [32]. FloSeal was also used to control persistent postpar-
tum hemorrhage from implantation site with success [33, 34]. In a case series, by 
Chung et al. in 2017, of 11 patients with obstetrical hemorrhage, 10 were controlled 
with intrauterine Floseal, with only 1 failure that required hysterectomy [35].
Fibrin sealants have also been used as an adjunct to control hemostasis at the 
placental implantation site. In 2010, Fuglsang and Petersen [36], published a series 
of 15 cases in which all cases were complicated by placenta previa and delivered 
by cesarean section. All were complicated by persistent bleeding from the lower 
uterine segment. Hemostasis was controlled with the topical application of 
Tachosil [36].
Although most applications of topical hemostatic agents occur at the time of 
cesarean section or hysterectomy, they have also been used to control hemosta-
sis from vaginal and vulvar lacerations that occur following traumatic vaginal 
deliveries [37].
4.2 Gynecologic usage
Use of topical hemostatic agents is far more common in gynecologic surgery 
than in obstetrics. Common cases that may require use of topical hemostatic agents 
include hysterectomies, ovarian cystectomies myomectomy, endometriosis resec-
tion/ablation, incontinence procedures, and malignant debulking procedures. In 
these cases, advantages to use of topical hemostasis include fewer transfusions, 
improved visualization of the surgical field, and decreased operative time which 
can all potentially decrease morbidity and mortality [12].
There has been a trend over the past two decades towards application of mini-
mally invasive surgical approaches [38]. At our institution, for example, more than 
84% of hysterectomies are performed laparoscopically. If there is diffuse small 
vessel bleeding, bleeding near the ureter or adjacent to major vessels (such as in the 
parametrium), using a topical hemostatic agent may reduce the risk of conversion 
to laparotomy. A systematic review of topical hemostatic agents used in minimally 
invasive gynecologic surgery (MIGS) concluded that application of topical hemo-
static agents in MIGS procedures can decrease operative time, blood loss, and may 
ameliorate damage to ovarian function. However, more data is needed on usage of 
hemostatic agents during other procedures like myomectomy, hysterectomy, and 
adnexal surgery [39]. In cases whereressure, electrosurgery, suturing, or stapling, 
may not be feasible during minimally invasive procedures such as with diffuse small 
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vessel bleeding, bleeding near ureter or major vessels, usage of topical hemostatic 
agents may be another option before converting to laparotomy.
4.3 Hysterectomy
Hysterectomy is the most common major gynecological procedure. More than 
430,000 hysterectomies are performed in the United States every year. Most are 
performed for benign reasons [39].
Usage of hemostatic agents during laparoscopic or robotic hysterectomies has 
increased since introduction of fibrin sealants in the 1990’s. Minimally invasive 
hysterectomy typically has less blood loss than open hysterectomy, so indications 
for topical hemostatic use may be less clear [4]. Evidence suggests that use of 
topical hemostatic agents at the time of hysterectomy is controversial. A study by 
Kakos, et al. [40], evaluated factors associated with the usage of hemostatic agents 
during traditional laparoscopic or robotic hysterectomies. Findings from this study 
revealed that the usage of hemostatic agents at the time of traditional laparoscopic 
or robotic hysterectomy was not associated with aggregate differences in intra-
operative or postoperative bleeding metrics. Length of stay was also unchanged 
relative to similar hysterectomies performed without the routine use of hemostatic 
agents. Their findings supported the idea that surgeon’s usage of these products 
was for prophylaxis rather than treatment [40]. Similar findings were published by 
Obermair, et al. [41], who compared adverse events and surgical outcomes of hys-
terectomy with or without usage of gelatin –thrombin matrix (Surgiflo). Surgiflo 
neither prevented nor caused additional adverse events in women undergoing 
hysterectomies [41].
Watrowski,et al. [42], studied the impact of the use of intraoperative hemostatic 
gelatin –thrombin matrix (FloSeal, Baxter healthcare) on transfusion rates and 
short-term perioperative outcomes in gynecological surgery. They found that usage 
of these hemostatic agents was associated with significantly better short- term 
perioperative outcomes including, shortened surgical and hospital times, less post-
operative anemia, fewer blood transfusions, and reduced number of reoperations 
and ICU stays [42].
Despite the dogma that improved hemostasis can lead to improved clinical out-
comes, there is evidence demonstrating the potential harms of topical hemostatic 
agents if used inappropriately. Harris, et al. [43], performed a retrospective cohort 
study of hemostatic agents used during hysterectomy and risk of postoperative 
complications. Women who received a hemostatic agent (N = 4659) were compared 
to women who did not receive a topical hemostatic agent (N = 9316). Hemostatic 
agent usage was associated with an increased rate of hospital readmission. Among 
all hysterectomy approaches, hemostatic agents used during robotic- assisted 
laparoscopic hysterectomy associated with an increased predicted rate of blood 
transfusions, and increase predicted rate of pelvic abscess diagnosis, and increased 
predicted rate of hospital readmission, and increased predicted rate of re-operation 
Their conclusion was that hemostatic agents should be used carefully owing to 
associations with increased postoperative re-admissions and re-operations when 
used during hysterectomy [43]. This study, however, did not control for diagnosis, 
making malignancy a cofounder and limiting strong conclusions regarding risks 
of hemostatic agent use in hysterectomy for benign indications [22]. Harris et al., 
in a second large retrospective study, compared postoperative outcomes between 
cohorts of patients undergoing hysterectomy for benign indications that fulfilled 
a perioperative bundle of four criteria. These included a minimally invasive 
approach, appropriate preoperative antibiotics, operative duration of less than 
2 hours, and absence of intraoperative hemostatic agent use. Of all cohorts missing 
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only one of the four criteria, there was an association with a greater risk of post-
operative complications in hyterectomies for benign indications in which hemo-
static agents were used [44].
4.4 Myomectomy
Leiomyomas are the most common benign gynecologic tumor, with an estimated 
instance of 70–80% in women by the age 50 years [45, 46]. Most patients with 
leiomyomas are asymptomatic. For those with symptoms related to bulk, abnormal 
uterine bleeding, or infertility, there are typically multiple management options. 
These include: observation, medical management, uterine artery embolization, 
ablative procedures, and surgical resection. Surgical resection (in the absence of 
hysterectomy) is inclusive of hysteroscopic, laparoscopic, and open myomectomy. 
A variety of different medical techniques have been used to diminish blood loss 
during the myomectomy. These include vaginal prostaglandins, vasopressin, bupi-
vacaine with epinephrine, oxytocin, fibrin sealant coated suture, IV tranexamic 
acid, and GnRH analogs. The evidence presented here will focus on topical hemo-
static agents used during myomectomy.
A retrospective study by Barakat, et al. [47], found that 6.5% of patients under-
going an abdominal approach and 1.1% of patients undergoing a minimally invasive 
approach will require a blood transfusion. Approximately 2% would be converted 
to a laparotomy [47].
A variety of different medical techniques have been used to diminish blood loss 
during the myomectomy. These include vaginal prostaglandins, vasopressin, bupi-
vacaine with epinephrine, oxytocin, fibrin –sealant coated suture, IV tranexamic 
acid, GnRH analogs. For the purpose of this chapter review, the focus will be on 
hemostatic agents during myomectomy.
Raga, et al., did a review of Floseal compared to placebo in a randomized 
cohort of 50 women undergoing myomectomy. Estimated blood loss (EBL) was 
significantly decreased in the treatment group. Length of stay and intraoperative 
blood transfusions were also less in the treatment group. Postoperative hemoglobin 
was significantly higher in the treatment group [48]. Fibrin sealants have also been 
studied in myomectomy. Tisseel has been shown to decrease mean time to achieve 
hemostasis, operative time, EBL, and post-operative HgB change [49].
4.5 Endometriosis resection
Endometriosis is a benign chronic disease associated with pain, dyspareunia, 
and infertility. Surgical options for conservative treatment include electrocauteri-
zation of cyst wall, cystectomy, and laser vaporization of cyst wall. Laparoscopic 
ovarian cystectomy has a significantly reduced rate of recurrence and an increased 
pregnancy rate when compared to coagulation and laser ablation methods [50, 51]. 
The goals of endometriosis resection in reproductive aged women are pain control 
and enhancement of fertility. Topical hemostatic agents have been investigated as 
an alternative to bipolar cautery and suturing to control hemostasis during ovar-
ian cystectomy. The rationale is that there will be less trauma to the ovary and less 
impact on ovarian reserve [52–54]. A meta-analysis concluded that use of hemo-
static agents was associated with significantly less decline in ovarian reserve over 
bipolar dissection [55]. Choi, et al. [56], investigated the impact of topical hemo-
static agents and bipolar coagulation during laparoscopic ovarian endometriotic 
cyst resection on ovarian reserve by comparing the postoperative anti-mullerian 
hormone (AMH) levels. AMH was significantly decreased in both groups 3 months 
postoperatively. However, the rate of decrease in the bipolar coagulation group was 
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greater than that of the hemostatic sealant group [56]. These findings were further 
supported by a multi -centered, randomized controlled trial that showed no differ-
ence in operative outcomes, operative time, estimated blood loss or perioperative 
complications between the bipolar and topical hemostatic agent groups. Similarly, 
in both groups, postoperative AMH levels were lower than pre-operative AMH 
levels, but the rate of decline of AMH levels was greater in the bipolar group than in 
the hemostatic sealant group [57–59].
When peritoneal endometriosis is resected or ablated, there can be diffuse 
bleeding from multiple sites. Peritoneal endometriosis is frequently found in the 
deep pelvis on the surface of the uterosacral ligaments and over the path of the 
ureter. Controlling bleeding during these often complicated peritoneal resections 
can be challenging with conventional methods and application of topical hemo-
static agents may be helpful [60]. There is not strong evidence for or against use of 
topical hemostatic agents for this particular indication.
5. Risks of topical hemostatic agent use
Several case reports have discussed risks of hemostatic agent use in gynecologic 
surgery including abscess formation, mimickry of abscess or malignant disease, 
small-bowel obstruction, blood –borne disease transmission, thrombus formation, 
and allergic reactions [3, 17, 19, 22, 24, 61–63].
Abscesses, or mimickry of abscesses, on imaging, is the most commonly 
reported complications of topical hemostatic agents. Mechanical agents being the 
most frequently associated. Fagotti, et al., demonstrated a statistically significant 
association between oxidative regenerating cellulose (ORC) (Surgicel) and pelvic 
abscess formation (11.8% with ORC verses 1.7% without) [15].
Anderson, et al., in a retrospective cohort study examined all malignancy related 
hysterectomies, and hysterectomies for benign indications through all routes except 
vaginal. Gelatin-thrombin matrix (GTM) was used in 40% of cases. 3% developed 
abscess. Based on this, their recommendation was that liberal use of GTM should be 
used with caution in clean contaminated cases [15].
A large retrospective cohort study of over 17,000 patients, by Harris et al., 
examined the use of hemostatic agents during all routes of hysterectomy and eval-
uated risks of post-operative complications. Among all hysterectomy approaches, 
and after adjusting for demographic and surgical factors, hemostatic agent use 
during robotic assisted laparoscopic hysterectomy was associated with an increased 
predicted rate of blood transfusions, and increased predicted rate of pelvic abscess 
diagnosis, and increased predicted rate of hospital readmission, and an increased 
predicted rate of reoperation. Their conclusion was that hemostatic agent should 
be use carefully owing to associations with increased postoperative re-admissions 
and re-operations when use during hysterectomy [43].
Collections seen postoperatively on imaging may be misinterpreted as an 
abscess [15]. Interpretation as to whether its abscess versus normal degeneration 
of topical hemostatic agents may be aided by informing radiologist that topical 
hemostatic agents have been used [16]. An abscess typically has rim enhanced and 
air-fluid levels. Topical hemostatic agent degeneration usually has tightly packed 
gas bubbles which remain unchanged on serial exams with no rim enhancement or 
air-fluid levels [16]. Often, as mechanical hemostatic agents degenerate over time, 
they may be mistaken as granulomas or malignancy [17, 18].
The next most common complication associated with topical hemostatic agents 
is small-bowel obstruction secondary to inflammatory foreign body giant cell 
reaction. Symptoms may present on postoperative days 5–9 [29, 64]. To decrease the 
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chances of this occurring, as per package insert, excess topical hemostatic agents 
should be gently irrigated and removed.
Another concern regarding usage of biological agents is the potential for immu-
nological risks. Agents that contain bovine thrombin have been associated with 
antibody –mediated reactions that have resulted in bleeding diatheses [65].
Donor pool human derived thrombin, approved in 2007 by the FDA, may 
potentially carry risk of viral disease transmission including HIV, hepatitis, 
parvovirus B19.
Recombinant thrombin may eliminate the risk of disease transmission and 
decreased immunologic response. However, allergic reactions to animal proteins 
have been reported [23].
6. Conclusion
Topical hemostatic agents should be used as an adjunct to good surgical 
technique. There are many potential applications of topical hemostatic agents in 
obstetrics and gynecology. Choice of topical hemostatic agent is at the discretion 
of the clinician and subject to hospital availability and cost. Mechanical hemostatic 
agents are passive and augment endemic clotting factors. Biologic hemostatic 
agents are active because they contain thrombin allowing better clot stabilization. 
Combining mechanical and biologic hemostatic agents (often done at the product 
level) can improve efficacy at a higher price point. Although the goal of these agents 
is to improve postoperative outcomes, there is limited evidence to support their 
widespread use in obstetrics and gynecology. In-depth knowledge of the risks and 
benefits of these agents is important because appropriate use has the potential to 
improve clinical outcomes. Since hemostatic agents have been introduced, they have 
been applied across many subspecialties, including Obstetrics and Gynecology. 
Knowledge of their mechanisms of actions, potential complications from their use, 
and limited and often conflicting data behind case-specific applications, warrants 
judicious usage of these agents. Larger studies, specifically on case- specific usage, 
along with focus on value-based applications, need to be done before empiric 
recommendations on routine usage of these agents can be made. At this point they 
should only be used as an adjunct to traditional means of achieving hemostasis.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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